NCT05660109View on ClinicalTrials.gov

A Study to Assess the Safety of TPM502 in Adults With Celiac Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

December 12, 2022

Primary Completion Date

July 4, 2024

Study Completion Date

August 8, 2024

Conditions
Celiac Disease
Interventions
DRUG

TPM502

TPM502 contains 3 peptides each consisting of two overlapping T cell epitopes that encompass the major gluten epitopes for HLA-DQ2.5

OTHER

Placebo

Placebo

Trial Locations (8)

4066

Wesley Research Institute, Brisbane

5000

Royal Adelaide Hospital, Adelaide

9038

University Hospital of North-Norway, Tromsø

12200

Charite' Hospital, Berlin

FI-20520

CRST Oy, Turku

2333 ZA

Centre for Human Drug Research, Leiden

0372

Oslo University Hospital HF - Rikshospitalet, Oslo

752 37

Clinical Trial Consultants, Uppsala University, Uppsala

All Listed Sponsors
lead

Topas Therapeutics GmbH

INDUSTRY